Stentys announced on July 4 that it had hired Christophe Lottin as CEO.
Lottin is a salesman and executive with more than 20 years experience in cardiology at Boston Scientific and Hexacath France. He will take over for Gonzague Issenmann during the next quarter. Issenmann and Jacques Séguin founded Stentys in 2006 to develop stents to treat acute MI.
In 2010, Stentys received a CE marking for its self-apposing BMS and DES(P) stents. The company has also received a CE mark for the Stentys aspiration catheter and the MiStent SES coronary drug-eluting stent.
The FDA has not yet approved any of Stentys’s products. However, the company announced in October 2012 that the FDA had granted an investigational device exemption to conduct a trial evaluating the Stentys self-apposing stent.
In October 2015, Stentys presented results of a trial examining its seroliums-eluting, self-apposing coronary stent at the Transcatheter Cardiovascular Therapeutics conference in San Francisco. The researchers randomized patients to receive the Stentys stent or Medtronic’s Resolute stent.
Three years after patients received the Stentys stent to treat STEMI, the mean in-stent late lumen loss was 0.08 mm, the rate of well-apposed struts was 99.3 percent and the rate of strut covered by tissue was 99.7 percent.
Stentys's headquarters are in Paris. The company also has offices in nine other countries, including a U.S. site in Princeton, N.J.